Branded Pharmaceuticals Q1 Earnings Mixed: Eli Lilly Soars, Zoetis Stumbles

Earnings
โดย Yahoo Finance·Read original
Summary · why it matters

Branded pharmaceutical stocks reported mixed first-quarter results, with the group beating revenue estimates by 3.6% on average. Eli Lilly led the pack with revenue of $19.8 billion, up 55.5% year-on-year and exceeding expectations by 13.7%, while Zoetis posted the weakest performance with revenue of $2.26 billion, up 2.9% but missing estimates by 2.1%. Organon revenue fell 3.5% to $1.46 billion, Supernus Pharmaceuticals grew 38.6% to $207.7 million, and Pfizer rose 5.4% to $14.45 billion. Since reporting, Eli Lilly shares have surged 41.1%, while Zoetis shares have dropped 35.8%.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 3 stocks
Eli Lilly and Company
LLY
▲ PositiveCapitalrelevance

Eli Lilly reported Q1 revenue of $19.8B, up 55.5% YoY and beating estimates by 13.7%, driving shares up 41.1%.

Pfizer Inc
PFE
▲ PositiveCapitalrelevance

Pfizer revenue rose 5.4% to $14.45B, beating estimates.

Health Care▼ · 2 stocks
Organon & Co
OGN
▼ NegativeCapitalrelevance

Organon revenue fell 3.5% to $1.46B, missing estimates.

Zoetis Inc
ZTS
▼ NegativeCapitalrelevance

Zoetis revenue of $2.26B missed estimates by 2.1%, and shares dropped 35.8%.

© 2026 MarketDXNews